KYTX (Kyverna Therapeutics) Marketable Securities : $214.62 Mil (As of Jun. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Kyverna Therapeutics Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Kyverna Therapeutics's Marketable Securities for the quarter that ended in Jun. 2024 was $214.62 Mil.

Kyverna Therapeutics's annual Marketable Securities increased from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($13.59 Mil) and increased from Dec. 2022 ($13.59 Mil) to Dec. 2023 ($22.90 Mil).

Kyverna Therapeutics Marketable Securities Historical Data

The historical data trend for Kyverna Therapeutics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyverna Therapeutics Marketable Securities Chart

Kyverna Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Marketable Securities

13.59

22.90

Kyverna Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Marketable Securities	Get a 7-Day Free Trial				-	54.31	22.90	145.51	214.62

Kyverna Therapeutics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Kyverna Therapeutics (NAS:KYTX) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Kyverna Therapeutics Marketable Securities Related Terms

Thank you for viewing the detailed overview of Kyverna Therapeutics's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Kyverna Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kyverna Therapeutics Inc (NAS:KYTX) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

5980 Horton Street, STE 550, Emeryville, CA, USA, 94608

Website

https://www.kyvernatx.com

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR.

Kyverna Therapeutics Headlines

From GuruFocus

Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering

By PRNewswire • 02-12-2024